Skip to content

Effectiveness of Kunlishu ® Kushen gel in the treatment of vulvovaginal candidiasis (VVC)-Multicenter, prospective, randomized, double-blind, placebo-controlled study

Effectiveness of Kunlishu ® Kushen gel in the treatment of vulvovaginal candidiasis (VVC)-Multicenter, prospective, randomized, double-blind, placebo-controlled study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086257
Enrollment
Unknown
Registered
2024-06-27
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

VVC

Interventions

control group:Fluconazole + Kushen gel placebo
treatment group:Fluconazole + Kushen gel

Sponsors

Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Women aged 18-50 years (including the threshold) with a sexual life history; 2. The results of vaginal secretion test indicate that candida (mycelium/pseudomycelium/budding) is positive; 3. Contraception during the trial, and the contraceptive method is barrier contraception; 4. Agree to refrain from using any other vaginal products (contraceptive creams, foams, sponges, lubricants, douches, etc.) throughout the trial period; 5. Patients with follow-up conditions, good compliance and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients during pregnancy, lactation, pregnancy preparation and menopause; 2. Patients with recurrent VVC (RVVC) who had four or more episodes of symptomatic VVC within one year; 3. Combined with cervical diseases, such as cervical inflammation, cervical precancer, cervical cancer, confirmed high-risk human papillomavirus (HPV) infection or cervical intraepithelial neoplasia of grade 2 or 3 (CIN2, CIN3); 4. Combine other diseases that doctors believe can cause vulvovaginal symptoms; 5. Patients with autoimmune diseases or poorly controlled diabetes; 6. Those who have used antifungal drugs in the past 2 weeks or have had a history of vulvovaginal medicine and irrigation; 7. Patients identified by the investigators as unsuitable for participation in the study.

Design outcomes

Primary

MeasureTime frame
Itch disappearance time;

Secondary

MeasureTime frame
cure rate;Symptom resolution time;VVC score;Proportion of subjects whose symptoms disappeared;Proportion of subjects whose symptoms improved;Candida clearance;recurrence rate;Vaginal microecological indicators;

Countries

China

Contacts

Public ContactLiu Zhaohui

Beijing Obstetrics and Gynecology Hospital, Capital Medical University

nannan_0428@163.com+86 136 9358 9280

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026